Can Sequential Administration Minimise the Cost of High Dose Chemotherapy?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: To evaluate the potential cost savings of using sequential high dose chemotherapy (HDC), with granulocyte colony-stimulating factor (filgrastim) and stem cell support, rather than single course administration of HDC with bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT).
Perspective: French public hospital perspective.
Methods: Direct medical costs of sequential treatment, estimated on the basis of physical quantities of resources consumed by 95 patients with inflammatory breast cancer (IBC) included in a French pilot multicentric trial (PEGASE 02), were compared with those of historical control groups of patients treated with single course HDC, either with BMT (n = 27) or PBSCT (n = 14). Costs were evaluated in 1998 French francs (1 € = 6.55957 French francs).
Results: The total cost of sequential HDC was significantly lower than that for single course HDC both with BMT (−29%; €22 755 vs €32 284; p < 0.001) or PBSCT (−16%; €22 755 vs €27209; p = 0.026). This was mainly due to a reduction in the length of hospitalisation in transplantation units.
Conclusion: According to our results, economic arguments cannot be used against the widespread use of sequential HDC for patients with IBC. However, further economic evaluations based on overall and disease-free survivals alongside a randomised clinical trial are still needed to definitively establish the cost effectiveness of sequential administration of HDC.
- Jaiyesimi IA, Buzdra AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10: 1014–24
- Barker J, Montague E, Peters L. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 1980; 45: 625–9 CrossRef
- Rouëssé J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4 (12): 1765–71
- Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach: MD Anderson Cancer Center experience. Cancer Chemotherapy Pharmacology 1990; 27: 94–100 CrossRef
- Eder JP, Amman K, Peters W, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4 (11): 1592–7
- Peters WP, Ross M, Vredenburgh JJ, et al. High dose chemotherapy and autologous bone marrow support for breast cancer as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1995; 11: 1132–43
- Ayash LJ, Wheeler C, Fairclough D. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043–9
- Ayash LJ, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cells support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000–7
- Viens P, Penault-Llorca F, Jacquemier J, et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249–54 CrossRef
- Cagnoni PJ, Nieto Y, Shpall EJ, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16 (5): 1661–8
- Macquart-Moulin G, Viens P, Palangie T, et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 2000 Feb; 18 (4): 754–64
- Le Corroller A-G, Moatti J-P, Chabannon C, et al. Optimization of peripheral blood stem cell collection by leukapheresis: a case of interaction between economic and clinical assessment of an innovation. Int J Technol Assess Health Care 1999; 15 (1): 161–72 CrossRef
- Basser RL, Bik To L, Glenn Begley C, et al. Adjuvant treatment of high risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Clin Cancer Res 1995; 1: 715–21
- Swain SM, Rowland J, Weinfurt K, et al. Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life. J Clin Oncol 1996; 14: 1565–72
- Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 1999; 81 (3): 449–56 CrossRef
- Uyl-de-Groot CA, Richel DJ, Rutten FF. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation. Eur J Cancer 1994; 30A (11): 1631–5 CrossRef
- Le Corroller A-G, Faucher C, Auperin A, et al. Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease. Pharmacoeconomics 1997; 11 (5): 454–63 CrossRef
- Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood-progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-hodgkin’s lymphoma. J Clin Oncol 1997; 15 (1): 5–10
- Le Corroller AG, Macquart-Moulin G, Auquier P, et al. Etude comparative des coûts de deux procédures de recueil des cellules souches hématopoïétiques: la cytaphérèse et le prélèvement de moelle osseuse. Revue Epidemiol Same Publique 1996; 44: 133–43
- Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96 (1): 102–9
- Drummond M, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programs. 2nd ed. Oxford: Oxford University Press, 1997
- Decrets, arrêtés, circulaires textes génénaux. Journal Officiel de la République Française 1998 Aout 1; 76: 11799
- Nomenclature générale des actes professionnels. Paris, UCANSS, 1998
- Palangié T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994; 30A (7): 921–7 CrossRef
- Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995; 180 (3): 297–306
- Nieto Y, Cagnoni PJ, Bearman SL. High-dose chemotherapy (HDC) with cisplatin (CDDP) cyclophosphamide (CPA) and BCNU (CCB), followed by autologous hematopoietic progenitor cell support (AHPCS) for inflammatory breast cancer (IBC) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 436
- Rosti G, Vertogen B, Ferrante P. High-dose mitoxantrone, thiopeta and cyclophosphamide with peripheral blood progenitor cells (PBPC) support for inflammatory breast carcinoma: an Italian study [abstract]. Proc Am Soc Clin Oncol 1997, 16; 125
- Meisenberg BR, Ferran K, Hollenbach K, et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927–32 CrossRef
- Astier MP, Mayordomo JI, Abad JM, et al. Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors. Ann Oncol 2000; 11: 603–6 CrossRef
- Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578–81
- Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995, 1571
- Can Sequential Administration Minimise the Cost of High Dose Chemotherapy?
Volume 21, Issue 11 , pp 807-818
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Inserm Research Unit 379, Institut Faoli-Calmettes, 232, Boulevard de Sainte Marguerite, 13 273, Marseilles Cedex 9, France
- 2. Institut Curie, Paris, France
- 3. Centre René Huguenin, Saint Cloud, France
- 4. Centre Paul Lamarque, Montpellier, France
- 5. Centre Claudius Regaud, Toulouse, France
- 6. Centre François Baclesse, Caen, France
- 7. Institut Paoli-Calmettes, Marseilles, France